cimzia
ucb pharma sa - sertolitsumabipegoli - crohnin tauti - immunosuppressantit - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate. cimzia voidaan antaa monoterapiana, jos potilas ei siedä metotreksaattia tai metotreksaattihoidon jatkaminen on sopimatonta. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.
adynovate rurioctocog alfa pegol (rch) 2000 iu powder for injection vial with diluent vial
takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.
adynovate rurioctocog alfa pegol (rch) 1000 iu powder for injection vial with diluent vial
takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.
adynovate rurioctocog alfa pegol (rch) 500 iu powder for injection vial with diluent vial
takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.
adynovate rurioctocog alfa pegol (rch) 250 iu powder for injection vial with diluent vial
takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.
pegorel 75 mg tabletki powlekane
s-lab sp. z o.o. - clopidogrelum besilate - tabletki powlekane - 75 mg
evorel 50mcg/24h transdermal patch
janssen-cilag international nv (0000003494) turnhoutseweg, 30, beerse, b-2340 - estradiol - transdermal patch - 50mcg/24h - estradiol (0000050282) 3.2mg - estradiol
evorel
janssen-cilag gmbh (8009839) - estradiol-hemihydrat - transdermales pflaster - teil 1 - transdermales pflaster; estradiol-hemihydrat (27668) 3,2 milligramm
evorel tts
janssen-cilag gmbh (8009839) - estradiol - transdermales pflaster - teil 1 - transdermales pflaster; estradiol (00232) 3,2 milligramm
evorel conti patches
theramex hq uk ltd - norethisterone acetate; estradiol - transdermal patch - 170microgram/24hour ; 50microgram/24hour